Brandy R. Murray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brandy R. Murray has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Adrian R. Black
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
39 shared publications - Benjamin Swanson
University of Nebraska Medical Center 5 Department of Pathology, Microbiology, and Immunology Omaha, Nebraska
39 shared publications - Christabelle Rajesh
Medical University of South Carolina 4 Department of Biochemistry and Molecular Biology Charleston, South Carolina
39 shared publications - Cory L. Brooks
California State University Fresno
39 shared publications - David R. Goodlett
Department of Biochemistry and Microbiology, University of Victoria
39 shared publications - Eric K. Lei
Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada
39 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S3. MUC16 expression in PDAC cells and PDAC patients’ samples using huAR9.6 mAb. (A) Western blotting for MUC16 (with huAR9.6) in normal HPDE cells and AsPC-1, T3M4, Capan-2, Panc-1, MiaPaCa-2, Capan-1, BxPC-3, S2-013, FG and SU86.86 PDAC cells. Loading control: α-tubulin. (B) Immunofluorescent staining for MUC16 (AF647-huAR9.6, red) and α-tubulin (AF488, green) in T3M4-WT and T3M4-MUC16KO cells. (C) Representative image of immunofluorescent staining for MUC16 (AF647-huAR9.6, red) in normal pancreas (n=7) and PDAC tissue (n=32) obtained from the Rapid Autopsy Program at UNMC. (D) Representative images of immunohistochemistry for MUC16 on a patient-derived xenograft (PDX) microarray using huAR9.6; (E) Graphical representation of varying histoscores; (F) Graphical representation of consistency between histoscore (huAR9.6-based MUC16 detection) and RNA sequencing of MUC16 gene expression in PDX microarray samples (n = 31). (G) Western blotting for MUC16 (with huAR9.6) in ascites fluids (n = 34) obtained from PDAC patients via the Rapid Autopsy Program at UNMC. Western blot of N-glycanase, O-glycanase and sialidase treated (H) T3M4 cell lysates and (I) MUC16 TR1.2 glycopeptides probed with huAR9.6 mAb. Detection of α-tubulin served as the loading control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S3. MUC16 expression in PDAC cells and PDAC patients’ samples using huAR9.6 mAb. (A) Western blotting for MUC16 (with huAR9.6) in normal HPDE cells and AsPC-1, T3M4, Capan-2, Panc-1, MiaPaCa-2, Capan-1, BxPC-3, S2-013, FG and SU86.86 PDAC cells. Loading control: α-tubulin. (B) Immunofluorescent staining for MUC16 (AF647-huAR9.6, red) and α-tubulin (AF488, green) in T3M4-WT and T3M4-MUC16KO cells. (C) Representative image of immunofluorescent staining for MUC16 (AF647-huAR9.6, red) in normal pancreas (n=7) and PDAC tissue (n=32) obtained from the Rapid Autopsy Program at UNMC. (D) Representative images of immunohistochemistry for MUC16 on a patient-derived xenograft (PDX) microarray using huAR9.6; (E) Graphical representation of varying histoscores; (F) Graphical representation of consistency between histoscore (huAR9.6-based MUC16 detection) and RNA sequencing of MUC16 gene expression in PDX microarray samples (n = 31). (G) Western blotting for MUC16 (with huAR9.6) in ascites fluids (n = 34) obtained from PDAC patients via the Rapid Autopsy Program at UNMC. Western blot of N-glycanase, O-glycanase and sialidase treated (H) T3M4 cell lysates and (I) MUC16 TR1.2 glycopeptides probed with huAR9.6 mAb. Detection of α-tubulin served as the loading control.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Figure S7. huAR9.6 mediates tumor burden reduction by targeting the MUC16-ErbB signaling axis and the apoptotic cascade. (A) IHC for pErbB3 (Y1289), pErbB2 (Y1248), pErbB1 (Y1173) and pAKT (S473) in subcutaneous tumor tissues obtained from mice treated with vehicle (PBS) and huAR9.6 (500 µg/25 g bodyweight, i.p.). Histoscore quantification of (B) pErbB3, (C) pErbB2, (D) pErbB1 and (E) pAKT staining. (F) IHC for pErbB3 (Y1289), pErbB2 (Y1248), pAKT (S473) in patient-derived organoids treated with vehicle (PBS), isotype control huIgG and huAR9.6 (40 µg/mL for 24 h). (G) IHC for cleaved caspase 3 in subcutaneous tumor tissues obtained from mice treated with vehicle (PBS) and huAR9.6 (500 µg/25 g bodyweight, i.p.) (n=5). (H) Histoscore quantification of cleaved caspase 3. Scale bar 50 µm. Mean ± SD, p < 0.05 was considered as statistically significant using the Student’s t-test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Figure S7. huAR9.6 mediates tumor burden reduction by targeting the MUC16-ErbB signaling axis and the apoptotic cascade. (A) IHC for pErbB3 (Y1289), pErbB2 (Y1248), pErbB1 (Y1173) and pAKT (S473) in subcutaneous tumor tissues obtained from mice treated with vehicle (PBS) and huAR9.6 (500 µg/25 g bodyweight, i.p.). Histoscore quantification of (B) pErbB3, (C) pErbB2, (D) pErbB1 and (E) pAKT staining. (F) IHC for pErbB3 (Y1289), pErbB2 (Y1248), pAKT (S473) in patient-derived organoids treated with vehicle (PBS), isotype control huIgG and huAR9.6 (40 µg/mL for 24 h). (G) IHC for cleaved caspase 3 in subcutaneous tumor tissues obtained from mice treated with vehicle (PBS) and huAR9.6 (500 µg/25 g bodyweight, i.p.) (n=5). (H) Histoscore quantification of cleaved caspase 3. Scale bar 50 µm. Mean ± SD, p < 0.05 was considered as statistically significant using the Student’s t-test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S10. Conservation of AR9.6 epitope in homologous SEA domains. The epitope deduced from the X-ray structure of AR9.6 in complex with SEA5 (yellow ribbon diagram) occurs in 3 regions of the protein (shown in orange). (A) Alignment of SEA5 with homologous MUC16 SEA domains reveals that the epitope is well conserved among SEA domains 3-13, (B) less well conserved in SEA domains 1-2 (C), and the least conserved in SEA domains 13,14,16. (D) No significant epitope conservation occurs in SEA domain 15.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S10. Conservation of AR9.6 epitope in homologous SEA domains. The epitope deduced from the X-ray structure of AR9.6 in complex with SEA5 (yellow ribbon diagram) occurs in 3 regions of the protein (shown in orange). (A) Alignment of SEA5 with homologous MUC16 SEA domains reveals that the epitope is well conserved among SEA domains 3-13, (B) less well conserved in SEA domains 1-2 (C), and the least conserved in SEA domains 13,14,16. (D) No significant epitope conservation occurs in SEA domain 15.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S5. RNA sequencing of PDAC cells. (A) Volcano plot showing upregulated (1145) and downregulated (183) genes in T3M4-WT and T3M4-MUC16KO cells (n=3); (B) Gene set enrichment analysis (GSEA) plot showing enrichment of apoptosis in T3M4-MUC16KO cells. (C) Log2FoldChange (Lof2FC) of MUC16KO versus WT and (D) Fragments Per Kilobase of transcript per Million (FPKM) of genes affected in EGF signaling pathway. p < 0.05 was considered as statistically significant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S5. RNA sequencing of PDAC cells. (A) Volcano plot showing upregulated (1145) and downregulated (183) genes in T3M4-WT and T3M4-MUC16KO cells (n=3); (B) Gene set enrichment analysis (GSEA) plot showing enrichment of apoptosis in T3M4-MUC16KO cells. (C) Log2FoldChange (Lof2FC) of MUC16KO versus WT and (D) Fragments Per Kilobase of transcript per Million (FPKM) of genes affected in EGF signaling pathway. p < 0.05 was considered as statistically significant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Figure S11 – Summary of HuAR9.6 Proposed Mechanism of Action. . In summary, huAR9.6 mAb binds with MUC16 positive PDAC and reduces tumor growth via 1) inhibiting the activation of MUC16-mediated ErbB signaling, and 2) inducing antibody-dependent cytotoxicity (ADCC) and 3) complement-dependent cytotoxicity (CDC).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Figure S11 – Summary of HuAR9.6 Proposed Mechanism of Action. . In summary, huAR9.6 mAb binds with MUC16 positive PDAC and reduces tumor growth via 1) inhibiting the activation of MUC16-mediated ErbB signaling, and 2) inducing antibody-dependent cytotoxicity (ADCC) and 3) complement-dependent cytotoxicity (CDC).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S4. huAR9.6 effects on PDAC cells and PDXs. Representative wound healing assay of vehicle (PBS), isotype control huIgG (40 µg/mL) and huAR9.6 (40 µg/mL) treated (A) T3M4 and (B) Capan-1 cells. (C) Schematic of patient-derived xenograft (PDX) derived cells obtained from primary human PDAC and liver metastasis. (D) Flow cytometric assessment of apoptosis using the Annexin-V/PI assay in T3M4 and Capan-1 cells treated with vehicle (PBS), isotype control huIgG (40 µg/mL) and huAR9.6 (40 µg/mL). Mean ± SD (n=3), p < 0.05 was considered as statistically significant using one-way ANOVA with Tukey’s multiple comparisons.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S4. huAR9.6 effects on PDAC cells and PDXs. Representative wound healing assay of vehicle (PBS), isotype control huIgG (40 µg/mL) and huAR9.6 (40 µg/mL) treated (A) T3M4 and (B) Capan-1 cells. (C) Schematic of patient-derived xenograft (PDX) derived cells obtained from primary human PDAC and liver metastasis. (D) Flow cytometric assessment of apoptosis using the Annexin-V/PI assay in T3M4 and Capan-1 cells treated with vehicle (PBS), isotype control huIgG (40 µg/mL) and huAR9.6 (40 µg/mL). Mean ± SD (n=3), p < 0.05 was considered as statistically significant using one-way ANOVA with Tukey’s multiple comparisons.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S2. Representative deuterium uptake plots of SEA5 regions with significantly reduced deuteration owing to interaction with mAR9.6 and huAR9.6
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S2. Representative deuterium uptake plots of SEA5 regions with significantly reduced deuteration owing to interaction with mAR9.6 and huAR9.6
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S9. Evaluation of huAR9.6’s potential toxicity. Liver enzyme profile showing (A) ALT and (B) AST measured in vehicle control (PBS), huIgG and huAR9.6 (500 µg/25 g bodyweight, i.p. for 4 doses) treated orthotopic PDAC tumor-bearing mice (n=5). (C) Representative H&E staining of liver, lung, spleen, and kidney collected from the vehicle control (PBS), huIgG and huAR9.6-treated orthotopic PDAC tumor-bearing mice (n=7) on day 28. (D) Schematic of a single-dose toxicity model in athymic nude mice (n=6). Blood collection was done on day 0 (pre-treatment), after which mice were treated with a single dose of vehicle (PBS) or huAR9.6 (1 mg/25 g bodyweight, i.p.), followed by blood collection on days 3 and 14. Body weight measurements were done daily. At the experimental endpoint (day 14), mice were euthanized. (E) Body weight measurements in grams (g) for mice treated with single-dose vehicle (PBS) or huAR9.6 (1 mg/mL). Day 0 serves as the pre-treatment timepoint. Liver enzyme profile showing (F) ALT and (G) AST measured in serum at pre-treated, 3- and 14-days post treatment timepoints. (H) Representative H&E staining of pancreas, liver, lung, spleen, and kidney collected from mice 14 days after single-dose treatment with vehicle or huAR9.6 (1 mg/mL).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Fig. S9. Evaluation of huAR9.6’s potential toxicity. Liver enzyme profile showing (A) ALT and (B) AST measured in vehicle control (PBS), huIgG and huAR9.6 (500 µg/25 g bodyweight, i.p. for 4 doses) treated orthotopic PDAC tumor-bearing mice (n=5). (C) Representative H&E staining of liver, lung, spleen, and kidney collected from the vehicle control (PBS), huIgG and huAR9.6-treated orthotopic PDAC tumor-bearing mice (n=7) on day 28. (D) Schematic of a single-dose toxicity model in athymic nude mice (n=6). Blood collection was done on day 0 (pre-treatment), after which mice were treated with a single dose of vehicle (PBS) or huAR9.6 (1 mg/25 g bodyweight, i.p.), followed by blood collection on days 3 and 14. Body weight measurements were done daily. At the experimental endpoint (day 14), mice were euthanized. (E) Body weight measurements in grams (g) for mice treated with single-dose vehicle (PBS) or huAR9.6 (1 mg/mL). Day 0 serves as the pre-treatment timepoint. Liver enzyme profile showing (F) ALT and (G) AST measured in serum at pre-treated, 3- and 14-days post treatment timepoints. (H) Representative H&E staining of pancreas, liver, lung, spleen, and kidney collected from mice 14 days after single-dose treatment with vehicle or huAR9.6 (1 mg/mL).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Figure S8. huAR9.6 induces ADCC and CDC in PDAC cells. (A) Flow cytometry-based assay showing ADCC against CFSE-labeled T3M4, Capan-2 and T3M4-MUC16KO cells via FVD (viability stain) CFSE double positive cells following incubation with peripheral blood mononuclear cells (PBMCs, effector cells) with or without the huAR9.6 antibody (B) Flow cytometry-based assay showing CDC against target T3M4, Capan-2 and T3M4-MUC16KO cells using Annexin-V/PI staining following incubation with human healthy donor derived serum with or without the huAR9.6 antibody.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6
Figure S8. huAR9.6 induces ADCC and CDC in PDAC cells. (A) Flow cytometry-based assay showing ADCC against CFSE-labeled T3M4, Capan-2 and T3M4-MUC16KO cells via FVD (viability stain) CFSE double positive cells following incubation with peripheral blood mononuclear cells (PBMCs, effector cells) with or without the huAR9.6 antibody (B) Flow cytometry-based assay showing CDC against target T3M4, Capan-2 and T3M4-MUC16KO cells using Annexin-V/PI staining following incubation with human healthy donor derived serum with or without the huAR9.6 antibody.